Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

BioAtla, Inc.. (BCAB)

Sector - Healthcare

Price chart

+183.06%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company developing their novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their conditionally active biologics, or CABs, capitalize on their proprietary discoveries with respect to tumor biology, enabling them to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Their novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic, and they have designed their antibodies to selectively bind to their targets on tumor cells under acidic pH conditions but not on targets in normal tissues. Their approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity -- one of the fundamental challenges of existing cancer therapies. The broad applicability of their CAB technology allows them to develop a wide array of product candidate modalities, such as monoclonal antibodies, antibody-drug conjugates, or ADCs, T cell-engaging bispecific antibodies and chimeric antigen receptor T cells, or CAR-T cells.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Jay M. Short Richard A. Waldron
Employees Founded
36 2007

Contacts

Address: 11085 Torreyana Road San Diego, California 92121

Telephone: (858) 558-0708

Web page: http://www.bioatla.com

IPO information

Expected Date 12/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 9.4
Shares Revised (MM) 10.5
Expected offer amount (MM) $150.4
Realized offer amount(MM) $189

Financial Data (last reporting year)

Market Cap (MM) $495.84
Revenues (MM) $2.63
Net Income (Loss) (MM) $-20.9

Voting

What do you think will happen with the BCAB share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ Jefferies/ Credit Suisse
CO-Managers
BTIG

Sector: Healthcare

Tweets about $BCAB

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats